Integra LifeSciences IART ENT — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's ent — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's ENT — total revenues?
- Integra LifeSciences (IART) reported ENT — total revenues of $37.71M in Q1 2026.
- How has Integra LifeSciences's ENT — total revenues changed year-over-year?
- Integra LifeSciences's ENT — total revenues decreased by 2.8% year-over-year, from $38.8M to $37.71M.
- What is the long-term trend for Integra LifeSciences's ENT — total revenues?
- Over 3 years (2022 to 2025), Integra LifeSciences's ENT — total revenues has grown at a 71.7% compound annual growth rate (CAGR), from $32.87M to $166.37M.
- What does ENT — total revenues mean?
- This metric represents the total net revenue generated by the Ear, Nose, and Throat (ENT) product segment. It reflects the market demand and commercial performance of specialized medical devices and solutions tailored for otolaryngology applications. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the company's ENT portfolio within the broader medical technology market.